A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Doses Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic/Pharmacodynamics Characteristics of MY008211A Tablets in Healthy Adult Volunteers
Latest Information Update: 12 Sep 2023
At a glance
- Drugs MY-008211A (Primary)
- Indications IgA nephropathy; Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; First in man
- Sponsors Wuhan Createrna Science and Technology
Most Recent Events
- 05 Sep 2023 Number of treatment arms increased from 5 to 7 by the addition of 2 new arms for 2 additional dose levels.
- 05 Sep 2023 Status changed from active, no longer recruiting to completed.
- 15 Dec 2022 New trial record